JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis
- 1Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China
- 2Department of Dermatology, Shenzhen Longhua District Central Hospital, Shenzhen, China
- 3The First School of Clinical Medicine, Southern Medical University, Guangzhou, China
- 4Department of Rheumatology, Dermatology Hospital, Southern Medical University, Guangzhou, China
A corrigendum on
JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis
by Hou, Z., Su, X., Han, G., Xue, R., Chen, Y., Chen, Y., Wang, H., Yang, B., Liang, Y., and Ji, S. (2022). Front. Med. 9:859330. doi: 10.3389/fmed.2022.859330
In the published article, there was an error regarding the affiliations for author “Xuehan Su.” As well as having the affiliation “Department of Dermatology, Dermatology Hospital, Southern Medical University, Guangzhou, China,” they should also have “The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.”
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: baricitinib, JAK inhibitor, systemic sclerosis, skin fibrosis, digital ulcers
Citation: Hou Z, Su X, Han G, Xue R, Chen Y, Chen Y, Wang H, Yang B, Liang Y and Ji S (2023) Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis. Front. Med. 9:1125836. doi: 10.3389/fmed.2022.1125836
Received: 16 December 2022; Accepted: 20 December 2022;
Published: 05 January 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Hou, Su, Han, Xue, Chen, Chen, Wang, Yang, Liang and Ji. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yunsheng Liang, yunshengliang@aliyun.com; Suyun Ji,
gddhjisuyun@smu.edu.cn
†These authors have contributed equally to this work and share first authorship